

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/ NINE MONTHS ENDED 31 DECEMBER 2010

(Rs. in lacs)

Sr. No.	Particulars	Quarter ended		Nine Months ended		Year ended (Audited)
		31.12.2010	31.12.2009	31.12.2010	31.12.2009	31.03.2010
1	a) Net Sales / Income from operations	10,146.74	8,597.26	28,190.30	26,302.82	34,942.03
	b) Other operating income	60.19	25.12	109.95	80.95	97.84
	Total (1)	10,206.93	8,622.38	28,300.25	26,383.77	35,039.87
2	Expenditure					
	a) (increase) / decrease in stock in trade	(563.33)	404.17	(1,625.86)	(193.22)	(794.94)
	b) Consumption of raw materials	7,120.44	5,406.57	19,142.78	17,654.79	24,082.48
	c) Purchase of traded goods	9.22	--	145.27	611.96	679.30
	d) Employees cost	396.98	288.35	1,180.19	831.59	1,125.07
	e) Depreciation	601.77	251.64	1,798.19	760.05	1,001.12
	f) Other expenditure	1,449.95	1,245.21	4,428.79	4,564.32	5,996.51
	Total (2)	9,015.03	7,595.94	25,069.36	24,229.49	32,089.54
3	Profit from operations before other income, interest and exceptional items (1-2)	1,191.90	1,026.44	3,230.89	2,154.28	2,950.33
4	Other income	0.45	0.45	1.35	1.35	1.80
5	Profit before interest and exceptional items (3+4)	1,192.35	1,026.89	3,232.24	2,155.63	2,952.13
6	Interest	973.91	388.06	2,715.34	1,097.26	1,486.74
7	Profit after interest but before exceptional items (5-6)	218.44	638.83	516.90	1,058.37	1,465.39
8	Exceptional items	--	--	--	--	--
9	Profit from ordinary activities before tax (7+8)	218.44	638.83	516.90	1,058.37	1,465.39
10	Tax Expenses	71.60	207.04	172.53	347.08	463.80
11	Net Profit from ordinary activities after tax (9-10)	146.84	431.79	344.37	711.29	1,001.59
12	Extraordinary Item (net of tax expense)	--	--	--	--	--
13	Net Profit for the period (11-12)	146.84	431.79	344.37	711.29	1,001.59
14	Paid-up equity share capital (Face value Rs.10/- Per Share)	2,571.67	2,121.67	2,571.67	2,121.67	2,271.67
15	Reserves excluding revaluation reserves	--	--	--	--	11,624.23
16	Earning per share (weighted)					
	- Basic	0.61	2.06	1.43	3.39	4.69
	- Diluted	0.61	2.06	1.43	3.39	4.68
	- Cash	3.22	3.72	9.17	7.80	12.29
17	Public shareholding					
	- No of shares	1,17,76,611	1,02,76,611	1,17,76,611	1,02,76,611	1,02,76,611
	- % age	45.79	48.44	45.79	48.44	45.24
18	Promoters and promoter group shareholding					
	a) Pledged/encumbered					
	- Number of shares	--	4,00,000	--	4,00,000	4,00,000
	- %age of the total promoters' shareholding	--	3.66	--	3.66	3.22
	- % age of the total shareholding	--	1.88	--	1.88	1.76
	b) Non-encumbered					
	- Number of shares	1,39,40,053	1,05,40,053	1,39,40,053	1,05,40,053	1,20,40,053
	- %age of the total promoters' shareholding	100.00	96.34	100.00	96.34	96.78
	- % age of the total shareholding	54.21	49.68	54.21	49.68	53.00

Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement

(Rs. in Lacs)

Sr. No	Particulars	Quarter ended		Nine Months ended		Year ended (Audited)
		31.12.2010	31.12.2009	31.12.2010	31.12.2009	31.03.2010
1	Segment Revenue (Net sales/income)					
	- Chemicals	6,666.35	5,300.18	17,699.82	17,847.44	23,166.83
	- Drugs	3,466.47	3,256.07	10,452.82	8,382.70	11,676.92
	- Unallocated	74.11	66.13	147.61	153.63	196.12
	Total	10,206.93	8,622.38	28,300.25	26,383.77	35,039.87
	Less : Inter segment revenue	--	--	--	--	--
	Net sales/income from operations	10,206.93	8,622.38	28,300.25	26,383.77	35,039.87
2	Segment Results					
	Profit/(loss) before tax and interest from each segment)					
	- Chemicals	889.98	537.42	2,091.69	1,274.50	1,396.21
	- Drugs	241.67	461.88	1,040.11	798.60	1,441.86
	Total	1,131.65	999.30	3,131.80	2,073.10	2,838.07
	Less :					
	Interest	973.91	388.06	2,715.34	1,097.26	1,486.74
	Other un-allocable expenditure net off un-allocable income	(60.70)	(27.59)	(100.44)	(82.53)	(114.06)
	Total Profit before tax & Extraordinary Items	218.44	638.83	516.90	1,058.37	1,465.39
3	Capital Employed					
	(Segment assets - Segment liabilities)					
	- Chemicals	28,378.60	7,307.51	28,378.60	7,307.51	25,770.21
	- Drugs	12,573.64	8,282.52	12,573.64	8,282.52	13,218.56
	- Unallocated including capital work in progress	8,815.07	27,039.90	8,815.07	27,039.90	3,458.39
	Total	49,767.31	42,629.93	49,767.31	42,629.93	42,447.16

Notes:

- The progress on the Implementation of multi purpose PPIs plant (anti-ulcerant drugs) and other pharmaceutical intermediate products with a CAPAX of Rs 130 crore is on schedule and has invested Rs 36.41 crore upto 15 January 2011 on the project.
- EBITDA margin has increased to 17.78% during the nine month period ended 31 December 2010 from 11.05% of corresponding nine months period ended 31 December 2009.
- Status of Investor's complaints for the quarter ended 31 December 2010 is as under:

Complaints at the beginning of quarter	Complaints received during the quarter	Complaints resolved	Complaints pending
Nil	Nil	Nil	Nil

- Tax expenses include current tax and deferred tax
- The figures of previous year have been regrouped/ rearranged wherever necessary.
- The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of the Directors at their meeting held on 08 February 2011 and limited review of the same has been carried out by statutory auditors of the Company

By order of the Board

For IOL Chemicals and Pharmaceuticals Limited

Place: Chandigarh
Date: 08 February 2011

Sd/-
(Varinder Gupta)
Chairman and Managing Director